Trial of Pirfenidone to Prevent Progression in Chronic Kidney Disease

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.

Also called NCT04258397

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose other
Phase
Phase 2
Enrolled
  • 200 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04258397
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT04258397. Randomized; triple masking; primary purpose other. Start 2020-10-26 (actual); primary completion 2024-05 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Trial of Pirfenidone to Prevent Progression in Chronic Kidney Disease
Acronym
TOP-CKD
Intervention (Drug)
Pirfenidone
Intervention (Drug)
matching placebo
Lead sponsor
Veterans Medical Research Foundation (class: other)
Collaborator
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (class: US National Institutes of Health)
Collaborator
San Diego Veterans Healthcare System (class: US federal agency)
Collaborator
University of California, San Diego (class: other)
Collaborator
University of California, San Francisco (class: other)
Collaborator
Genentech, Inc. (class: industry)

Record details

Record id
cardio:ct-nct04258397
Content hash
9357a94ffb32deeef9d8e50c8505220d2c246f74af863ac2b70a432ec61220b5